Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-12-01T02:40:16.059Z Has data issue: false hasContentIssue false
  • English
  • Français

The soluble ST2 levels in patients with depression and comorbid heart failure

Published online by Cambridge University Press:  01 September 2022

A. Sikora ,
S. Fedorov ,
M. Vynnyk ,
M. Pustovoyt ,
O. Pityk  and
J. Bezuk
A. Sikora*
Affiliation:
Ivano-Frankivsk National Medical University, Psychiatry, Narcology And Medical Psychology, Ivano-Frankivsk, Ukraine
S. Fedorov
Affiliation:
Ivano-Frankivsk National Medical University, Postgraduate Internal Medicine, Ivano-Frankivsk, Ukraine
M. Vynnyk
Affiliation:
Ivano-Frankivsk National Medical University, Psychiatry, Narcology And Medical Psychology, Ivano-Frankivsk, Ukraine
M. Pustovoyt
Affiliation:
Ivano-Frankivsk National Medical University, Psychiatry, Narcology And Medical Psychology, Ivano-Frankivsk, Ukraine
O. Pityk
Affiliation:
Ivano-Frankivsk National Medical University, Psychiatry, Narcology And Medical Psychology, Ivano-Frankivsk, Ukraine
J. Bezuk
Affiliation:
Ivano-Frankivsk National Medical University, Psychiatry, Narcology And Medical Psychology, Ivano-Frankivsk, Ukraine
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depression in HF has become a major issue as the burden of HF has continued to increase, and many studies have suggested poorer outcomes in HF patients reporting depression. The prevalence of major depression in HF is about 20–40 %, which is 4–5 % higher than in the normal population. Soluble ST2 is involved in multiple pathogenetic pathways including cardiac strain, inflammation, and myocardial necrosis with remodeling.

Objectives

The purpose of study was to assess the predictive effect of soluble ST2 (sST2) and depressive symptoms in patients with ischemic HF

Methods

It this observational cross-sectional trial 129 patients with ischemic HF FC II-IV by New York Heart Association and depression were investigated. The diagnosis was verified by laboratory and instrumental methods according to European Society of Cardiology recommendations (2016). Depressive symptoms were evaluated by the Hospital Anxiety and Depression Scale. The ST2 level in blood serum was detected by ELISA method. Statistical analyses were performed using the Statistica 12 (StatSoft, Tulsa, OK, USA).

Results

The prevalence of depression increases with NYHA functional class. With decreasing ejection fraction of left ventricle, levels of sST2 were gradually increased (P for trend < 0.001), as well as the prevalence of depressive symptoms (P for trend < 0.01). Multivariate Cox regression analysis demonstrated that depressive symptoms and elevation of sST2 were both independent predictors of all-cause mortality and HF-related hospitalization.

Conclusions

The serum levels of sST2 and depressive symptoms were independent and additive predictors of all-cause mortality and heart failure-related hospitalization in patients with ischemic HF.

Disclosure

No significant relationships.

Keywords

Heart FailureNurobiological FactorsDepressioncomorbidity
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S111 - S112
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.